Consultation on publication of new cancer waiting times statistics Summary Feedback Report

Similar documents
Cancer Waiting Times in NHSScotland

Project Brief. New Cancer Waiting Times. Data Quality Assurance Audit

Cancer Waiting Times in NHSScotland

Cancer Waiting Times in NHSScotland

Cancer Waiting Times in NHSScotland

Ovarian Cancer Quality Performance Indicators

Access to Male & Female Sterilisation

Upper GI Cancer Quality Performance Indicators

HPV Immunisation Uptake Statistics for the Catch-up Programme

Scottish Bowel Screening Programme Statistics

Testicular Cancer Quality Performance Indicators

Scottish Cancer Taskforce: National Cancer Quality Steering Group Cancer Clinical Audit

Activity Report April 2012 to March 2013

IVF Waiting Times Publication

Dementia Post- Diagnostic Support

Acute Leukaemia Quality Performance Indicators

Mortality amenable to Health Care in Scotland

Scotland s Sexual Health Information, SSHI Health Protection Scotland Slide Set

ADHD Medication Prescribing in Scotland in 2016/17

Lung Cancer Quality Performance Indicators

Colorectal Cancer Quality Performance Indicators

Activity Report April 2012 March 2013

Sexually Transmitted Infection, including HIV, Health Protection Scotland Slide Set

HPV Immunisation Statistics Scotland

breast screening explained

Dear Colleague. DL (2017) June Additional Funding for CGMs and Adult Insulin Pumps Summary

SUBJECT: HPV vaccination programme update

Teenage Booster Immunisation Statistics

Dental Earnings and Expenses: Scotland, 2011/12

IMMUNISATION PROGRAMMES IN NHS GREATER GLASGOW AND CLYDE

HPV Immunisation Statistics Scotland

Activity Report April 2013 March 2014

Health & Social Care Research Strategy

Activity Report April 2013 March 2014

NHS Smoking Cessation Service Statistics (Scotland) 1 st January to 31 st December 2011

Teenage Booster Immunisation Statistics Scotland

CANCER IN SCOTLAND: ACTION FOR CHANGE The structure, functions and working relationships of Regional Cancer Advisory Groups

Injecting Equipment Provision in Scotland Survey 2011/12

NHS Smoking Cessation Service Statistics (Scotland) 1 st January to 31 st December 2006

Scottish Abdominal Aortic Aneurysm Screening Programme Statistics

Mental Health Collaborative. Dementia Summary of Activity. April 2010

Mental Health Collaborative. Dementia Summary of Activity. October 2009

Teenage Booster Immunisation Statistics

Activity Report April 2014 March 2015

Audit Report. Report of the 2014 Clinical Audit Data. North, South East and West of Scotland Cancer Networks

Long Acting Reversible Methods of Contraception (LARC) in Scotland

Activity Report March 2013 February 2014

abcdefghijklmnopqrstu

Peripheral Arterial Disease

Better Cancer Care, An Action Plan. Cancer Waiting Times Standards Data & Definitions Manual Version April 2012

Audit Report Report of the 2015 Clinical Audit Data

Population Based KCIs Data for 2006

Scottish Diabetes Survey

Child Health Month Review Statistics

NHS Smoking Cessation Service Statistics (Scotland) 1 st January to 31 st December 2008

NHSScotland Psychology Services

ScotPHO Tobacco Profiles Second release (January 2015)

Long Acting Reversible Methods of Contraception (LARC) Key Clinical Indicator

Long Acting Reversible Methods of Contraception (LARC) Key Clinical Indicator

NHSScotland Psychology Services

Drug-Related Hospital Statistics Scotland 2014/15

Survey Scottish Diabetes. Survey Monitoring Group

Long Acting Reversible Methods of Contraception (LARC) Key Clinical Indicator

Scottish Diabetes Survey 2012

Better Cancer Care, An Action Plan. Cancer Waiting Times Standards Data & Definitions Manual Version January 2017

Scottish Clinical Coding Standards

Surveillance of Surgical Site Infection Annual Report For procedures carried out from: January December 2010

Child Health Month Review Statistics

Epidemiological notes Susan Vaughan

Scottish Bowel Screening Programme Statistics

SCAN Skin Group Friday 1 st November 2013

Scottish Bowel Screening Programme Statistics

National Drug and Alcohol Treatment Waiting Times

abcdefghijklm abcde abc a eé~äíü=aéé~êíãéåí= cêçã=íüé= `ÜáÉÑ=jÉÇáÅ~ä= lññáåéê= = aê=e~êêó=_ìêåë=jme=co`pedä~ëf= co`mebçf=ccme= Dear Colleague

Scottish Pathology Network (SPAN) Progress Report Oct 2008

National Drug and Alcohol Treatment Waiting Times

National Naloxone Programme Scotland

Health Protection Scotland

Director of Public Health Board Paper No. 12/43. Report of the Director of Public Health : Childhood Immunisation and Staff Flu Vaccination Programmes

Report prepared on behalf of the Scottish Head and Neck Cancer Networks by the WoSCAN Information Team

Attention Deficit and Hyperkinetic Disorders. Services Over Scotland. Final Report November Scrutiny

Scottish Diabetes Survey

National Naloxone Programme Scotland Monitoring Report naloxone kits issued in 2011/12

Primary 1 Body Mass Index (BMI) Statistics

WHERE NEXT FOR CANCER SERVICES IN SCOTLAND?

Activity Report July 2014 June 2015

Annual Report April 2016 March 2017

Supporting public involvement and community engagement Examples of how Scottish Health Council local offices supported NHS Boards in

NATIONAL MANAGED CLINICAL NETWORK FOR ADULT NEURO-ONCOLOGY ANNUAL REPORT 2010/11

Increasing the Proportion of Women using Long Acting Reversible Contraception (LARC) within a Geographical Area in Scotland

Characteristics of the Workforce Supply in 2004

Cancer Waiting Times. 1 April Adjuvant Radical External Beam Radiotherapy Definitions. Version 1.0

Scottish Stroke Improvement Plan. Prof Martin Dennis Chair of National Advisory Committee

The Development of a Pre Hospital Mental Health Course for Remote and Rural Practitioners.

abcdefghijklmnopqrstu

Shingles (herpes zoster) vaccine programme in Scotland for 2016/17

Audit Report. Breast Cancer Quality Performance Indicators. Patients diagnosed during Published: February 2018

Scottish Abdominal Aortic Aneurysm Screening Programme. December 2017 National Review

Scottish Public Health Network (ScotPHN) Eye Conditions in Scotland Report 1: Estimates of Current and Future. Cathy Johnman

Transcription:

Consultation on publication of new cancer waiting times statistics Summary Feedback Report Information Services Division (ISD) NHS National Services Scotland March 2010 An electronic version of this document is available at http://www.isdscotland.org/isd/5013.html

Introduction In October 2008 the Scottish Government published Better Cancer Care An Action Plan 1, where it announced 2 new targets to be delivered by 2011: Extend the 62 day urgent referral to treatment target to include patients who had screened positive and all patients urgently referred with a suspicion of cancer. Introduce a new 31 day target for all patients diagnosed with cancer (no matter how they were referred) from decision to treat to treatment. To remain relevant to the changing set of targets the existing cancer waiting times statistics will need to be replaced with a new series of figures. We produced a consultation document which summarised ISD s proposals for the new series of official statistics due to be published from June 2010. This document sought feedback from actual or prospective users of the statistics, to make sure the published statistics would best suit user needs; in particular what statistics should be published and how they should be laid out. The consultation period lasted just over 10 weeks and this report presents the summary of findings and the finalised layout, format and content of the future publication tables. Summary of Findings ISD received 46 feedback responses from the consultation on publication of new cancer waiting times statistics. Of the 46 total responses, 31 (67%) were valid; that is that questions were answered and comments made. Analysis of the consultation feedback is based on valid responses only. Over half (56%) of the respondents class their organisation as NHS Board (territorial), 16% work in the Cancer Charity sector, 10% within Other UK Government organisation; whilst Academia, Audit Scotland, Information Services Division (ISD) Scotland, NHS National Services Scotland (NSS excluding ISD), NHS Board (special excluding NSS), and the Scottish Government each represent 3% of the remaining responders. Finalised tables showing performance against the targets Eighty three percent of respondents agreed that the proposed layout of tables 1 and 2 showing quarterly performance against the 62 day and 31 day target by Network/board and cancer types met their needs in full. Eighty seven percent of respondents said that they were happy with the proposed presentation of trend data (Table 3). When asked for any further views/comments on tables 1 3, responders made comments such as, the layouts looked clear, simple, helpful, and easy to understand. Some responders asked for additional data or further breakdowns of the data to be displayed, for example: ineligible patients, other specific cancer diagnoses, breakdown of urology, aggregated yearly reports. 1 http://www.scotland.gov.uk/publications/2008/10/24140351 1

Taking the further comments into account, we feel that providing extra information, for example ineligible patients; is unnecessary, as there is not enough demand. Also, information on those included in the target and exclusions are available in tables 5 and 6. We are unable to provide other cancer diagnoses such as Haematological malignancies. Although we capture data specifically for lymphoma, the current dataset does not allow for more specific diagnoses; only the existing cancer types listed. Another responder asked for a more detailed breakdown of cancer type, for example prostate cancer. Our dataset has the functionality to further breakdown Urology into: Urology Bladder, Urology Prostate, and Urology Other. We intend to look at further detailed splits of the existing cancer types if there is sufficient demand, and we may expand the current dataset in the future to include further cancer types. We were also asked if we could produce aggregated yearly reports as well as quarterly reports. All four quarters of data will be published on the website, so our users can calculate yearly figures. If there is enough demand from customers, we may produce yearly reports in the future. It also emerged that most respondents felt that the trend data (Table 3) would be more useful if we provided information by individual cancer type. However, tables 1 and 2 already provide this level of detail so we will not repeat this in Table 3. Therefore, these tables will be published as proposed, with the exception of Table 3. We will use a suggestion made by one of the responders to improve the layout of Table 3 by removing the numerator (number treated within 62/31) and displaying all the denominators (number of referrals and percentage treated within 62/31 ) together by Board and Network, and all the percentages together by Board and Network. Further statistics for lengths of wait will be provided in Tables 1 3, as discussed on Page 4. (See appendices A and B, pages 6 9 for the finalised layouts of Tables 1 3.) Finalised graphs and tables showing overall distribution of waiting times Figure 1 and Table 4 present the distribution of waiting times data: 67% of respondents said Yes they were happy with the distribution of waiting times data proposals, 17% stated No, 13% had No opinion either way, and one respondent (3%) from an Other UK Government organisation replied Don t know. We received lots of differing comments when respondents were asked to give further opinions on Figure 1 and Table 4. Conflicting views ranged from Figure 1 being classed as useful and a good representation of the data; to it being of limited use. Table 4 generally received more constructive feedback such as it is more useful than Figure 1 but could be improved by displaying numbers as well as percentages. Many responders asked for Figure 1 and Table 4 to be broken down by Board and Network level for individual cancer types and by referral source. They also raised concerns that the table provided too much detail and could be misinterpreted. 2

After considering all responders views, we deemed that it would not be feasible or appropriate to produce the graph and table for each Board/Network and individual cancer type/referral source, given the small number of cases involved for some Boards and cancer types. Therefore, we will publish Figure 1 at a national level only for all cancers combined. We will act on further comments received by changing the graph to look at patients treated, rather than those still waiting, and to add a footnote about the tolerance level. Table 4 will also be published at national level only for individual cancer types due to the larger discrete time bands involved. Specific comments regarding the baskets of in Table 4 have also been taken into account, as these were not evenly spread. We have improved these baskets by standardising the ranges. The 62 day target table will be comprised of five bands using the following range: 0 20, 21 41, 42 62, 63 83, and 84 or more. The 31 day target table have four bands employing the following range: 0 15, 16 31, 32 47, and 48 or more. We will also take on board the comments from responders and insert an extra column showing the number of eligible referrals as well as the percentages. (See appendices C and D, pages 10 11 for the finalised layouts of Figure 1 and Table 4.) Finalised tables showing exclusions and waiting times adjustments Seventy nine percent of responders broadly agreed with ISD's proposals to publish data on exclusions and adjustments (tables 5 and 6). Many stated that everything should be published for transparency. Several opposing comments were also received saying that this information should not be published until the new definitions are consistently applied across Scotland, or should only published for NHS use initially. There were also concerns that we will need a lot of explanation to explain these exclusions and adjustments, and that it may be difficult for the public to understand. Others suggested that this type of information should be included as general information and not as a specific table. Twenty two percent of responders thought that we should not include referrals not covered by the target as this may lead to confusion. Presenting data on the total referrals and the number of referrals not covered by the 62 day target is in keeping with the New Ways approach of being clear that there are patients who go through the system but who are not covered by this waiting times target. We appreciate that there are concerns that the column listing Total Referrals will not itself count everyone going through the system, and that it may introduce other complexities for the publication to explain. However, the consideration here was openness and transparency of the statistics in line with the UK Statistics Authority (UKSA) principles. 3

Feedback from our consultation responders showed us that 82% thought we should publish Total referrals and 70% for referrals not covered by the target. Therefore we will publish all the information contained in tables 5 and 6. However, we intend to change the Total referrals column heading to Total referrals submitted (Urgent & Non urgent referrals) and Referrals not covered by the 62 day target to Non urgent referrals to be clearer. We will also action improvements suggested by the responders, by adding the percentage of exclusions and separating the adjustments to identify patient and medical delays. (See appendices E and F, pages 12 15 for the finalised layouts of Tables 5 and 6.) Further statistics to be included in the publications As well as the figures outlined under Proposed tables showing performance against the targets, responders were also asked whether they thought that the publication should include further statistics about lengths of wait. Although 61% of responders said that the publication should include additional statistics for lengths of wait, views differed as to what these should be. After analyses of all responses, and taking the responders further comments into account; we will use the maximum, median and 90 th percentile. The maximum and median waits had more support than the other statistics. We are using the 90 th percentile rather than the 95 th percentile to be consistent with other waiting times data published. Another factor is that we need more patients to calculate a 95 th percentile, which may be impractical with the small numbers involved for some boards and cancer types. General Comments We would also like to address some of the general and other comments we received. Most responders (86%) stated that downloadable Excel files would meet their needs. However, responders also asked for CSV and PDF files, and HTML format. We intend to provide data in PDF files and HTML format where possible and appropriate. Many responders asked for the screening information to be reported separately. There will be separation of patients referred from a screening service. This will allow these figures to be assessed separately as this information is first published. Information presented at NHS Board and regional Cancer Network level in the 31 day tables will be reflected separately for the Golden Jubilee National Hospital, but will be included within the Scotland total. Analyses of responders comments also emphasised that we need to provide more informative: table titles, column headings, footnotes and explanatory text specifying all the inclusion/exclusion criteria, sensitivity of small numbers, waiting times adjustments, and interpretation notes in more depth to make this information clearer for our users. ISD will work closely with our Scottish Government colleagues to aid interpretation for all our customers. 4

To make this information more functional, accessible and user friendly for our users we will also use filters/drop down menus to select information for a particular Board, Network, cancer type, or indicator for some of the tables. Finally, all the information presented at Board, Network and cancer type level will be subject to disclosure consideration, and may not be published at all of these levels. In our role as provider of information to a wide range of customers including the NHS, Government, researchers, charities, the media and members of the public, we recognise that we may receive ad hoc requests for alternative or more detailed information, and will handle these requests under existing arrangements for information requests and disclosure control. 5

Appendices Appendix A: Finalised table outline for performance against new 62 day target Table 1: Performance against the 62 day target from receipt of an urgent referral with a suspicion of cancer to first cancer treatment by NHS Board and regional Cancer Network Period of treatment: 1 st January to the 31 st March 2010 All cancer types* Title will automatically change when user selects a different Cancer Type Select Cancer Type: All cancers Select drop down box for Cancer Type Area of receipt of referral Number of eligible referrals 1 Number treated within 62 Percentage treated within 62 Maximum wait Median wait 90th Percentile Scotland ZZZZ ZZZZ ZZ.Z% ZZZZ ZZZZ ZZZZ NOSCAN 2 YYYY YYYY YY.Y% YYYY YYYY YYYY Grampian 0000 0000 00.0% 0000 0000 0000 Highland 0000 0000 00.0% 0000 0000 0000 Orkney 0000 0000 00.0% 0000 0000 0000 Shetland 0000 0000 00.0% 0000 0000 0000 Tayside 0000 0000 00.0% 0000 0000 0000 Western Isles 0000 0000 00.0% 0000 0000 0000 SCAN 3 YYYY YYYY YY.Y% YYYY YYYY YYYY Borders 0000 0000 00.0% 0000 0000 0000 Dumfries & Galloway 0000 0000 00.0% 0000 0000 0000 Fife 0000 0000 00.0% 0000 0000 0000 Lothian 0000 0000 00.0% 0000 0000 0000 WOSCAN 4 YYYY YYYY YY.Y% YYYY YYYY YYYY Ayrshire & Arran 0000 0000 00.0% 0000 0000 0000 Forth Valley 0000 0000 00.0% 0000 0000 0000 Greater Glasgow & Clyde 0000 0000 00.0% 0000 0000 0000 Lanarkshire 0000 0000 00.0% 0000 0000 0000 Notes 1. Referrals covered by the 62 day target, excluding patients who had a clinically complex pathway, died before treatment or refused treatment. See Background for more information. 2. NOSCAN = North of Scotland CAncer Network 3. SCAN = South East Scotland CAncer Network 4. WOSCAN = West of Scotland CAncer Network *All cancer types for which data are recorded: breast, colorectal, head and neck, lung, lymphoma, melanoma, gynae ovarian, upper GI, urological, and gynae cervical (screen detected). YYYY or YY.Y% in the table above indicate subtotals by Cancer Network. ZZZZ or ZZ.Z% in the table above indicate totals for Scotland. This table will also be presented in an alternative format by listing Cancer Types and selecting Board and Network (see below): 6

Table 1: Performance against the 62 day target from receipt of an urgent referral with a suspicion of cancer to first cancer treatment by Cancer Type Period of treatment: 1 st January to the 31 st March 2010 NHS Scotland Title will automatically change when user selects a different Board/Network Select Board/Network: NHS Scotland Select drop down box for Board/Network Area of receipt of referral Number of eligible referrals 1 Number treated within 62 Percentage treated within 62 Maximum wait Median wait 90th Percentile All cancer types* ZZZZ ZZZZ ZZ.Z% ZZZZ ZZZZ ZZZZ Breast ZZZZ ZZZZ ZZ.Z% ZZZZ ZZZZ ZZZZ Colorectal 0000 0000 00.0% 0000 0000 0000 Head & Neck 0000 0000 00.0% 0000 0000 0000 Lung 0000 0000 00.0% 0000 0000 0000 Lymphoma 0000 0000 00.0% 0000 0000 0000 Melanoma 0000 0000 00.0% 0000 0000 0000 Gynae ovarian 0000 0000 00.0% 0000 0000 0000 Gynae cervical 0000 0000 00.0% 0000 0000 0000 Upper GI 0000 0000 00.0% 0000 0000 0000 Urological 0000 0000 00.0% 0000 0000 0000 Notes 1. Referrals covered by the 62 day target, excluding patients who had a clinically complex pathway, died before treatment or refused treatment. See Background for more information. *All cancer types for which data are recorded: breast, colorectal, head and neck, lung, lymphoma, melanoma, gynae ovarian, upper GI, urological, and gynae cervical (screen detected). ZZZZ or ZZ.Z% in the table above indicate totals for Scotland, Board and Cancer Network. These tables will be replicated for performance against the new 31 day target i.e. Table 2. 7

Appendix B: Finalised table outline for trend information on performance against targets Table 3: Trend performance against the 62 day target from receipt of an urgent referral with a suspicion of cancer to first cancer treatment by NHS Board and regional Cancer Network Period of treatment: Trend data from 1 st January to the 31 st March 2010 The number of eligible referrals 1 for all cancer types* Title will automatically change when user selects a different indicator, for example % treated within 62 Select Indicator Num ber of eligible referrals Select drop down box for indicator Area of receipt of referral 31 st Mar 2010 Patients first treated during quarter ending 30 th June 30 th Sept 31 st Dec 2010 2010 2010 31 st Mar 2011 Scotland ZZZZ ZZZZ ZZZZ ZZZZ ZZZZ NOSCAN 2 YYYY YYYY YYYY YYYY YYYY Grampian 0000 0000 0000 0000 0000 Highland 0000 0000 0000 0000 0000 Orkney 0000 0000 0000 0000 0000 Shetland 0000 0000 0000 0000 0000 Tayside 0000 0000 0000 0000 0000 Western Isles 0000 0000 0000 0000 0000 SCAN 3 YYYY YYYY YYYY YYYY YYYY Borders 0000 0000 0000 0000 0000 Dumfries & Galloway 0000 0000 0000 0000 0000 Fife 0000 0000 0000 0000 0000 Lothian 0000 0000 0000 0000 0000 WOSCAN 4 YYYY YYYY YYYY YYYY YYYY Ayrshire & Arran 0000 0000 0000 0000 0000 Forth Valley 0000 0000 0000 0000 0000 Greater Glasgow & Clyde 0000 0000 0000 0000 0000 Lanarkshire 0000 0000 0000 0000 0000 Notes 1. Referrals covered by the 62 day target, excluding patients who had a clinically complex pathway, died before treatment or refused treatment. See Background for more information. 3. NOSCAN = North of Scotland CAncer Network 4. SCAN = South East Scotland CAncer Network 5. WOSCAN = West of Scotland CAncer Network *All cancer types for which data are recorded: breast, colorectal, head and neck, lung, lymphoma, melanoma, gynae ovarian, upper GI, urological, and gynae cervical (screen detected). YYYY or YY.Y% in the table above indicate subtotals by Cancer Network. ZZZZ or ZZ.Z% in the table above indicate totals for Scotland. This table will also be presented in an alternative format by listing indicators and selecting Board and Network (see below): 8

Table 3: Trend performance against the 62 day target from receipt of an urgent referral with a suspicion of cancer to first cancer treatment by indicator type for all cancer types* Period of treatment: Trend data from 1 st January to the 31 st March 2010 NHS Scotland Title will automatically change when user selects a different Board/Network Select Board/Network: NHS Scotland Select drop down box for Board/Network Indicator 31 st Mar 2010 Patients first treated during quarter ending 30 th June 30 th Sept 31 st Dec 2010 2010 2010 31 st Mar 2011 Number of ZZZZ ZZZZ ZZZZ ZZZZ ZZZZ eligible referrals 1 % treated within ZZ.Z% ZZ.Z% ZZ.Z% ZZ.Z% ZZ.Z% 62 Maximum wait ZZZZ ZZZZ ZZZZ ZZZZ ZZZZ Median wait ZZZZ ZZZZ ZZZZ ZZZZ ZZZZ 90th Percentile ZZZZ ZZZZ ZZZZ ZZZZ ZZZZ Notes 1. Referrals covered by the 62 day target, excluding patients who had a clinically complex pathway, died before treatment or refused treatment. See Background for more information. *All cancer types for which data are recorded: breast, colorectal, head and neck, lung, lymphoma, melanoma, gynae ovarian, upper GI, urological, and gynae cervical (screen detected). ZZZZ or ZZ.Z% in the table above indicate totals for Scotland, Board and Cancer Network. These tables will also be replicated for performance against the new 31 day target. 9

Appendix C: Finalised graph showing distribution of waits Figure 1: Distribution of waits against the 62 day target from receipt of an urgent referral with a suspicion of cancer to first cancer treatment Period of treatment: 1 st January to the 31 st March 2010 NHS Scotland and all cancer types* Figure 1: NOTE THIS IS ILLUSTRATIVE THE GRAPH DOES NOT SHOW REAL DATA 100% Percentage of patients treated 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% 62 day target NOT REAL DATA 0 20 40 60 80 100 120 140 160 Days since receipt of referral *All cancer types for which data are recorded. As screen detected cancers and/or further cancer types are added to the target, the publications will highlight where there are discontinuities between graphs for patients treated in successive quarters. A tolerance level is applied to the new targets. The agreed tolerance level is 5% for each of these targets, that is the stated waiting time must be met for 95% of all patients covered by the target. For some patients it will not be clinically appropriate for treatment to begin within 62 of referral, for example, where a series of tests needs to be done in sequence, or for a difficult diagnosis that may require a series of interventions and a period of time to resolve. This figure will be replicated for performance against the new 31 day target. 10

Appendix D: Finalised table outline for statistics on distribution of waits Table 4: Distribution of waits against the 62 day target from receipt of an urgent referral with a suspicion of cancer to first cancer treatment by Cancer Type Period of treatment: 1 st January to the 31 st March 2010 NHS Scotland Cancer type 1 Length of wait from receipt of referral to first treatment 2 Number of eligible referrals 0 20 21 41 42 62 63 83 84 or more All cancer types* ZZZZ ZZ.Z% ZZ.Z% ZZ.Z% ZZ.Z% ZZ.Z% Breast ZZZZ 00.0% 00.0% 00.0% 00.0% 00.0% Colorectal 0000 00.0% 00.0% 00.0% 00.0% 00.0% Head & Neck 0000 00.0% 00.0% 00.0% 00.0% 00.0% Lung 0000 00.0% 00.0% 00.0% 00.0% 00.0% Lymphoma 0000 00.0% 00.0% 00.0% 00.0% 00.0% Melanoma 0000 00.0% 00.0% 00.0% 00.0% 00.0% Gynae ovarian 0000 00.0% 00.0% 00.0% 00.0% 00.0% Gynae cervical 0000 00.0% 00.0% 00.0% 00.0% 00.0% Upper GI 0000 00.0% 00.0% 00.0% 00.0% 00.0% Urological 0000 00.0% 00.0% 00.0% 00.0% 00.0% Table 4: Distribution of waits against the 31 day target from decision to treat to first cancer treatment by Cancer Type Period of treatment: 1 st January to the 31 st March 2010 NHS Scotland Cancer type 1 Length of wait from decision to treat to first treatment 2 Number of eligible referrals 0 15 16 31 32 47 48 or more All cancer types* ZZZZ ZZ.Z% ZZ.Z% ZZ.Z% ZZ.Z% Breast ZZZZ 00.0% 00.0% 00.0% 00.0% Colorectal 0000 00.0% 00.0% 00.0% 00.0% Head & Neck 0000 00.0% 00.0% 00.0% 00.0% Lung 0000 00.0% 00.0% 00.0% 00.0% Lymphoma 0000 00.0% 00.0% 00.0% 00.0% Melanoma 0000 00.0% 00.0% 00.0% 00.0% Gynae ovarian 0000 00.0% 00.0% 00.0% 00.0% Gynae cervical 0000 00.0% 00.0% 00.0% 00.0% Upper GI 0000 00.0% 00.0% 00.0% 00.0% Urological 0000 00.0% 00.0% 00.0% 00.0% Notes 1. May not be shown for all individual cancer types, due to small numbers. 2. Percentages shown in each row should add up to 100%. *All cancer types for which data are recorded. As screen detected cancers and/or further cancer types are added to the target, the publications will highlight where there are discontinuities between tables for patients treated in successive quarters. 11

Appendix E: Finalised table outline for information on exclusions and adjustments in respect of 62 day target Table 5: Exclusions and waiting times adjustments against the 62 day target from receipt of an urgent referral with a suspicion of cancer to first cancer treatment by NHS Board and regional Cancer Network Period of treatment: 1 st January to the 31 st March 2010 All cancer types* Area of receipt of referral Total referrals submitted 2 (Urgent & Non urgent referrals) Non urgent referrals 3 Urgent Referrals 4 Referrals covered by 62 day target Excluded from target calculations 5 Percentage exclusions Number of eligible referrals 6 Referrals included in analysis but with waiting time adjustment (WTA) made 7 Number Patient delay Medical delay Median Number Median adjustment 8 adjustment 8 Scotland ZZZZ ZZZZ ZZZZ ZZZZ ZZ.Z% ZZZZ ZZZZ ZZZZ ZZZZ ZZZZ NOSCAN YYYY YYYY YYYY YYYY YY.Y% YYYY YYYY YYYY YYYY YYYY Grampian 0000 0000 0000 0000 00.0% 0000 0000 0000 0000 0000 Highland 0000 0000 0000 0000 00.0% 0000 0000 0000 0000 0000 Orkney 0000 0000 0000 0000 00.0% 0000 0000 0000 0000 0000 Shetland 0000 0000 0000 0000 00.0% 0000 0000 0000 0000 0000 Tayside 0000 0000 0000 0000 00.0% 0000 0000 0000 0000 0000 Western Isles 0000 0000 0000 0000 00.0% 0000 0000 0000 0000 0000 SCAN YYYY YYYY YYYY YYYY YY.Y% YYYY YYYY YYYY YYYY YYYY Borders 0000 0000 0000 0000 00.0% 0000 0000 0000 0000 0000 Dumfries & Galloway 0000 0000 0000 0000 00.0% 0000 0000 0000 0000 0000 Fife 0000 0000 0000 0000 00.0% 0000 0000 0000 0000 0000 Lothian 0000 0000 0000 0000 00.0% 0000 0000 0000 0000 0000 WOSCAN 4 YYYY YYYY YYYY YYYY YY.Y% YYYY YYYY YYYY YYYY YYYY Ayrshire & Arran 0000 0000 0000 0000 00.0% 0000 0000 0000 0000 0000 Forth Valley 0000 0000 0000 0000 00.0% 0000 0000 0000 0000 0000 Greater Glasgow & Clyde 0000 0000 0000 0000 00.0% 0000 0000 0000 0000 0000 Lanarkshire 0000 0000 0000 0000 00.0% 0000 0000 0000 0000 0000 12

Notes on table 5 Each column in the table is labelled from A to I to help with the questions that we ask you later in this document and on the online consultation feedback form. 1. All cancer types currently covered by the target, these being: breast, colorectal, head & neck, lung, lymphoma, melanoma, ovarian, upper GI, urological and screendetected cervical cancers. *As screen detected cancers and/or further cancer types are added to the target, the data for these will also be reflected in the above totals. In these instances, ISD will also make clear in its publications where there are discontinuities between the All cancer types figures for one time period and the All cancer types figures for subsequent periods. 2. All referrals submitted where the patient started their first treatment during the stated time period, regardless of the referral route or source. 3. For example because the referral was not urgent or not from a screening programme. These referrals are however included in the 31 day target covering the time from decision to treat to start of first treatment. 4. For example because the patient was urgently referred with a suspicion of cancer by their GP or dentist. 5. Because the patient died before treatment, refused all treatment, or had a particularly complex clinical pathway. 6. This is the number of referrals for which performance against the 62 day target is monitored. 7. For patient induced delays (e.g. because they did not attend an appointment) or medical delays (e.g. the patient had another condition requiring treatment before cancer treatment could be started). 8. The median amount of time by which waiting times were adjusted where patients had an adjustment. 13

Appendix F: Finalised table outline for information on exclusions and adjustments in respect of 31 day target Table 6: Exclusions and waiting times adjustments against the 31 day target from decision to treat to first cancer treatment by NHS Board and regional Cancer Network Period of treatment: 1 st January to the 31 st March 2010 All cancer types* Area of first treatment Referrals in 31 day target cohort Referrals included in analysis but with waiting time adjustment (WTA) made 5 Patient delay Medical delay Number Median Urgent & Excluded Percentage Number of Number Median Non urgent from target exclusions eligible adjustment 6 adjustment 6 referrals 2 calculations 3 referrals 4 Scotland ZZZZ ZZZZ ZZ.Z% ZZZZ ZZZZ ZZZZ ZZZZ ZZZZ NOSCAN YYYY YYYY YY.Y% YYYY YYYY YYYY YYYY YYYY Grampian 0000 0000 00.0% 0000 0000 0000 0000 0000 Highland 0000 0000 00.0% 0000 0000 0000 0000 0000 Orkney 0000 0000 00.0% 0000 0000 0000 0000 0000 Shetland 0000 0000 00.0% 0000 0000 0000 0000 0000 Tayside 0000 0000 00.0% 0000 0000 0000 0000 0000 Western Isles 0000 0000 00.0% 0000 0000 0000 0000 0000 SCAN YYYY YYYY YY.Y% YYYY YYYY YYYY YYYY YYYY Borders 0000 0000 00.0% 0000 0000 0000 0000 0000 Dumfries & Galloway 0000 0000 00.0% 0000 0000 0000 0000 0000 Fife 0000 0000 00.0% 0000 0000 0000 0000 0000 Lothian 0000 0000 00.0% 0000 0000 0000 0000 0000 WOSCAN 4 YYYY YYYY YY.Y% YYYY YYYY YYYY YYYY YYYY Ayrshire & Arran 0000 0000 00.0% 0000 0000 0000 0000 0000 Forth Valley 0000 0000 00.0% 0000 0000 0000 0000 0000 Greater Glasgow & Clyde 0000 0000 00.0% 0000 0000 0000 0000 0000 Lanarkshire 0000 0000 00.0% 0000 0000 0000 0000 0000 National Waiting Times Centre (Golden Jubilee National Hospital) 0000 0000 00.0% 0000 0000 0000 0000 0000 14

Notes on table 6 1. All cancer types currently covered by the target, these being: breast, colorectal, head & neck, lung, lymphoma, melanoma, ovarian, upper GI, urological and screendetected cervical cancers. *As screen detected cancers and/or further cancer types are added to the target, the data for these will also be reflected in the above totals. In these instances, ISD will also make clear in its publications where there are discontinuities between the All cancer types figures for one time period and the All cancer types figures for subsequent periods. 2. All referrals submitted where the patient started their first treatment during the stated time period, regardless of the referral route or source. 3. Because the patient died before treatment, refused all treatment, or had a particularly complex clinical pathway. 4. This is the number of referrals for which performance against the 31 day target is monitored. 5. For patient induced delays (e.g. because they did not attend an appointment) or medical delays (e.g. the patient had another condition requiring treatment before cancer treatment could be started). 6. The median amount of time by which waiting times were adjusted where patients had an adjustment. 15